Human VEGF-D Quantikine ELISA Kit | hVEGF-D Qkit
掲載日情報：2016/08/18 現在Webページ番号：111229
R&D Systems製のHuman VEGF-Dを測定するELISAキットです。
※本製品は研究用です。研究用以外には使用できません。
[在庫・価格 ：2025年04月26日 15時15分現在]
| 詳細 | 商品名 |
|
文献数 | ||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
VEGF-D, Human, ELISA Kit, Quantikine (96well) |
|
31 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
[在庫・価格 ：2025年04月26日 15時15分現在]
VEGF-D, Human, ELISA Kit, Quantikine (96well)
文献数： 31
- 商品コード：DVED00
- メーカー：RSD
- 包装：1kit
- 価格：¥116,000
- 在庫：1個
- 納期：10日程度 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等：
| 説明文 | 測定範囲：125-4,000 pg/mL，感度：31.3 pg/mL，測定試料：Serum, Plasma, Cell Culture Supernatant，種交差性：Human，検出方法：呈色，測定波長：450 nm，アッセイ法：Solid Phase Sandwich ELISA，アッセイ数：96 well，別売品コントロール：#QC20，測定時間：4.5 hours，測定因子：VEGF-D 別名：c-fos induced growth factor (vascular endothelial growth factor D) Genbank No： 2277 |
||
|---|---|---|---|
| 法規制等 | |||
| 保存条件 | 4℃ | 法規備考 | |
| 掲載カタログ |
ニュース2019年12月15日号 p.3
|
||
| 製品記事 | R&D Systems社 VEGF-VEGF R2シグナル伝達系関連製品 ELISA Kit製品に関するFAQ（R&D Systems） |
||
| 関連記事 | R&D Systems Quantikine ELISA Kit／DuoSet Kit特集 Quantikine ELISA Kit |
||
追加しました。
Product Details
- Assay Type
- Solid Phase Sandwich ELISA
- Format
- 96-well strip plate
- Assay Length
- 4.5 hours
- Sample Type & Volume Required Per Well
- Cell Culture Supernates (50 µL), Serum (50 µL), EDTA Plasma (50 µL), Heparin Plasma (50 µL)
- Sensitivity
- 31.3 pg/mL
- Assay Range
- 125 - 4,000 pg/mL (Serum, Heparin Plasma, Cell Culture Supernates, EDTA Plasma)
- Specificity
- Natural and recombinant human VEGF-D
- Interference
- No significant interference observed with available related molecules.
追加しました。
Product Summary
The Quantikine Human VEGF-D Immunoassay is a 4.5 hour solid phase ELISA designed to measure VEGF-D levels in cell culture supernates, serum, and plasma. It contains Sf 21-expressed, recombinant human VEGF-D and antibodies raised against the recombinant protein. Results obtained for naturally occurring human VEGF-D showed linear curves that were parallel to the standard curves obtained using the kit standards. These results indicate that this kit can be used to determine relative mass values for natural human VEGF-D.
追加しました。
Precision
Intra-Assay Precision (Precision within an assay)
Three samples of known concentration were tested on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays)
Three samples of known concentration were tested in separate assays to assess inter-assay precision.
Serum, EDTA Plasma, Heparin Plasma
| Intra-Assay Precision | Inter-Assay Precision | |||||
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 40 | 40 | 40 |
| Mean | 448 | 970 | 2,081 | 474 | 956 | 2,013 |
| Standard Deviation | 27.8 | 40.9 | 49.3 | 38 | 68.5 | 145 |
| CV% | 6.2 | 4.2 | 2.4 | 8 | 7.2 | 7.2 |
| Intra-Assay Precision | Inter-Assay Precision | |||||
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 40 | 40 | 40 |
| Mean | 560 | 1,098 | 2,192 | 512 | 978 | 1,978 |
| Standard Deviation | 31.8 | 35.5 | 45.6 | 46.3 | 72.8 | 117 |
| CV% | 5.7 | 3.2 | 2.1 | 9 | 7.4 | 5.9 |
追加しました。
Recovery
The recovery of VEGF-D spiked to three different levels throughout the range of the assay in various matrices was evaluated.
| Sample Type | Average % Recovery | Range % |
| Serum (n=5) | 106 | 94-113 |
| Heparin Plasma (n=5) | 104 | 88-114 |
| EDTA Plasma (n=5) | 105 | 89-114 |
| Cell Culture Media (n=4) | 100 | 97-104 |
追加しました。
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of VEGF-D in various matrices and diluted with the appropriate Calibrator Diluent to produce samples with values within the dynamic range of the assay.
追加しました。
Additional Infomation
- Molecule Information
- VEGF-D
- Aliases
- FIGF
- Entrez Gene IDs
- 2277 (Human); 14205 (Mouse)
- Background
- VEGF-D
- Vascular endothelia growth factor D (VEGF-D), also known as c-fos-induced growth factor (FIGF), is a secreted glycoprotein of the VEGF/PDGF family. VEGFs regulate angiogenesis and lymphangiogenesis during development and tumor growth, and are characterized by eight conserved cysteine residues that form a cystine knot structure. VEGF-C and VEGF-D, which share 23% amino acid (aa) sequence identity, are uniquely expressed as preproproteins that contain long N- and C-terminal propeptide extensions around the VEGF homology domain (VHD). Proteolytic processing of the 354 aa VEGF-D preproprotein creates a secreted proprotein. Further processing by extracellular serine proteases, such as plasmin or furin-like proprotein convertases, forms mature VEGF-D consisting of non-covalently linked 42 kDa homodimers of the 117 aa VHD.Mature human VEGF-D shares 94%, 95%, 99%, 97% and 93% aa identity with mouse, rat, equine, canine and bovine VEGF-D, respectively. It is expressed in adult lung, heart, muscle, and small intestine, and is most abundantly expressed in fetal lungs and skin. Mouse and human VEGF-D are ligands for VEGF receptor 3 (VEGF R3, also called Flt-4) that are active across species and show enhanced affinity when processed. Processed human VEGF-D is also a ligand for VEGF R2, also called Flk-1 or KDR. VEGF R3 is strongly expressed in lymphatic endothelial cells and is essential for regulation of the growth and differentiation of lymphatic endothelium. While VEGF-C is the critical ligand for VEGF R3 during embryonic lymphatic development, VEGF-D is most active in neonatal lymphatic maturation and bone growth. Both promote tumor lymphangiogenesis. Consonant with their activity on VEGF receptors, binding of VEGF-C and VEGF-D to neuropilins contributes to VEGF R3 signaling in lymphangiogenesis, while binding to integrin α9β1 mediates endothelial cell adhesion and migration.
追加しました。
Citations
Citations of cell biology reagents in peer reviewed literature can be used as a direct measure of product quality. They can also provide crucial insightinto their use under specialized or unique experimental conditions. Because of the importance published citations have to researchers, R&D Systems personnelmanually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but alsoprovides information about sample types, species, and experimental conditions.
Co-expression of alpha9beta1 integrin and VEGF-D confers lymphatic metastatic ability to a human breast cancer cell line MDA-MB-468LN.
Bhattacharjee RN, Chambers AF, Lala PK, Majumder M, Rodriguez-Torres M, Timoshenko AV, Torres-Garcia J, Tutunea-Fatan E, Wiebe R, Xin X
PLoS ONE 2012 7:e35094
Species: Human
Sample Type: Cell Culture Supernates
Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis.
Respir. Res. 2012 13:34
Species: Human
Sample Type: Serum
Prognostic significance of angiogenic factors in uterine cervical cancer.
Blohmer JU, Heidecke H, Jeschke S, Korlach S, Kummel S, Landt S, Lichtenegger W, Schmid P, Sehouli J, Stoblen F, Wehling M
Anticancer Res. 2011 31:2589-95
Species: Human
Sample Type: Serum
Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease.
Ashwal S, Camposano S, Cutler D, Dabora SL, DiMario FJ, Fennessy F, Franz DN, Garber J, Krueger D, Lee N, Manola J, Miles D, Paolini J, Rabenou R, Sagalowsky A, Thiele EA, Uppot RN, Woodrum C
PLoS ONE 2011 6:e23379
Species: Human
Sample Type: Serum
Autocrine effects of VEGF-D on endothelial cells after transduction with AD-VEGF-D(DeltaNDeltaC).
Boncela J, Cierniewski CS, Papiewska-Pajak I, Przygodzka P
Exp. Cell Res. 2010 316:907-14
Species: Human
Sample Type: Cell Culture Supernates
Impaired lymphangiogenesis due to excess vascular endothelial growth factor-D/Flt-4 signalling in the skin of patients with systemic sclerosis.
Fukushima S, Honda N, Ihn H, Jinnin M, Kajihara I, Makino T
Br. J. Dermatol. 2010 163:776-80
Species: Human
Sample Type: Serum
Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.
Burger H, de Jonge MJ, Konings IR
Br. J. Cancer 2010 103:987-92
Species: Human
Sample Type: Serum
Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.
Avila NA, Glasgow CG, Lin JP, Moss J, Stylianou MP
Chest 2009 135:1293-300
Species: Human
Sample Type: Serum
Novel vascular endothelial growth factor D variants with increased biological activity.
Airenne KJ, Airenne TT, Alitalo A, Jauhiainen S, Johnson MS, Laitinen OH, Markkanen JE, Nieminen T, Roschier M, Salminen TA, Toivanen PI, Viitanen L, Yla-Herttuala S
J. Biol. Chem. 2009 284:16037-48
Species: Human
Sample Type: Cell Culture Supernates
Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines.
Hermanns MI, Jayasinghe C, Kirkpatrick CJ, Michel-Schmidt R, Peters K, Simiantonaki N
Int. J. Oncol. 2008 32:585-92
Species: Human
Sample Type: Cell Culture Supernates
追加しました。
製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。